Patents by Inventor Daniel Hunziker

Daniel Hunziker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW AZACYCLIC DERIVATIVES
    Publication number: 20100292212
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, m, A, R1 and R2 have the significance given in the description. The compounds are useful as HSL inhibitors and may be used in the treatment or prophylaxis of diabetes, dyslipidemia, atherosclerosis or obesity.
    Type: Application
    Filed: May 3, 2010
    Publication date: November 18, 2010
    Inventors: Jean Ackermann, Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch, Stanley Wertheimer
  • 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS
    Publication number: 20100249139
    Abstract: The present invention relates to compounds of formula I wherein R1a to R1e and R2 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.
    Type: Application
    Filed: March 19, 2010
    Publication date: September 30, 2010
    Inventors: Daniel Hunziker, Christian Lerner, Werner Mueller, Ulrike Obst Sander, Philippe Pflieger, Pius Waldmeier
  • 2,3-DIARYL- OR HETEROARYL-SUBSTITUTED 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS
    Publication number: 20100249124
    Abstract: The present invention relates to compounds of formula I wherein R1a to R1c, R2, R3 and R5 are as defined in the description and claims and R4 signifies a bicyclic heteroaryl group or a cyanophenyl group, as well as pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.
    Type: Application
    Filed: March 19, 2010
    Publication date: September 30, 2010
    Inventors: Daniel Hunziker, Christian Lerner, Werner Mueller, Ulrike Obst Sander, Philippe Pflieger, Pius Waldmeier
  • DPP IV inhibitors
    Patent number: 7803819
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: September 28, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
  • SUBSTITUTED PYRIDO [1,2-a] ISOQUINOLINE DERIVATIVES
    Publication number: 20100222340
    Abstract: The present invention relates to compounds of formula (I) wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Application
    Filed: May 13, 2010
    Publication date: September 2, 2010
    Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Fabienne Ricklin, Hans Peter Wessel
  • SALT AND POLYMORPH OF A DPP-IV INHIBITOR
    Publication number: 20100093808
    Abstract: The invention is concerned with (2S)-1-{[1,1-Dimethyl-3-(4-pyridin-3-yl-imidazol-1-yl)-propylamino]-acetyl}-pyrrolidine-2-carbonitrile fumarate and crystalline polymorphs of this compound. This compound and its polymorphic forms exhibits superior properties compared to the previously known compounds and can be used as medicament for the treatment of disorders which are associated with DPP-IV.
    Type: Application
    Filed: December 14, 2009
    Publication date: April 15, 2010
    Inventors: André Bubendorf, Olaf Grassmann, Daniel Hunziker, Holger Kuehne, Regina Moog, Urs Schwitter
  • 4-AMINOPIPERIDINE DERIVATIVES
    Publication number: 20100087485
    Abstract: The present invention relates to compounds of the formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or ?-cell protection.
    Type: Application
    Filed: December 9, 2009
    Publication date: April 8, 2010
    Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Thomas Luebbers, Fabienne Ricklin
  • 4-aminopiperidine derivatives
    Patent number: 7683079
    Abstract: The present invention relates to compounds of the formula (I) wherein R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or ?-cell protection.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: March 23, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Thomas Luebbers, Fabienne Ricklin
  • Pyridazines as 11b-HSD1 inhibitors
    Patent number: 7678795
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: July 5, 2006
    Date of Patent: March 16, 2010
    Assignee: Hoffman-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander V Mayweg, Werner Neidhart
  • Pyrazolones as 11b-HSD1 inhibitors for diabetes
    Patent number: 7652057
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: January 26, 2010
    Assignee: Hoffman-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander V Mayweg, Werner Neidhart
  • Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors
    Patent number: 7547697
    Abstract: Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof for use as pharmaceutical compositions.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: June 16, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Werner Neidhart, Alexander V. Mayweg
  • NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES
    Publication number: 20090149503
    Abstract: Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof used in the form of pharmaceutical compositions.
    Type: Application
    Filed: February 17, 2009
    Publication date: June 11, 2009
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
  • 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes
    Patent number: 7528159
    Abstract: Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: May 5, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
  • Indazolone derivatives useful as 11b-HSD1 inhibitors
    Patent number: 7528158
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R7 have the significances given in the description and claims can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: May 5, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Amrein, Jianping Cai, Robert Alan Goodnow, Jr., Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
  • GLUCOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20090088425
    Abstract: The present invention relates to compounds of formula I wherein A, n, R1a to R1e and R2 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.
    Type: Application
    Filed: September 15, 2008
    Publication date: April 2, 2009
    Inventors: Jacques Bailly, Cornelia Hertel, Daniel Hunziker, Christian Lerner, Ulrike Obst Sander, Jens-Uwe Peters, Philippe Pflieger, Tanja Schulz-Gasch
  • 11b-HSD1 inhibitors for the treatment of diabetes
    Patent number: 7507733
    Abstract: Compounds of the formula (I): as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: March 24, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
  • Pyridines
    Patent number: 7482341
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R6 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: September 29, 2005
    Date of Patent: January 27, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
  • Aminocycloalkanes as DPP-IV inhibitors
    Patent number: 7411093
    Abstract: The present invention relates to compounds of formula (I) wherein R1 is as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: December 13, 2005
    Date of Patent: August 12, 2008
    Assignee: Hoffman-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Bernd Kuhn, Bernd Michael Loeffler, Hans Peter Marty, Patrizio Mattei, Robert Narquizian
  • NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS
    Publication number: 20080103183
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R6 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
    Type: Application
    Filed: October 12, 2007
    Publication date: May 1, 2008
    Inventors: Jean Ackermann, Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart, Tadakatsu Takahashi
  • Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors
    Publication number: 20080009499
    Abstract: Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof for use as pharmaceutical compositions.
    Type: Application
    Filed: July 2, 2007
    Publication date: January 10, 2008
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander V. Mayweg, Werner Neidhart